Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers.
Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.
The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions.
It offers test services through physicians and their patients.
The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | -0.09 Increased by +91.82% | -0.33 Increased by +72.73% |
| Feb 28, 24 | -0.10 Increased by +87.18% | -0.54 Increased by +81.48% |
| Nov 2, 23 | -0.26 Increased by +66.23% | -0.76 Increased by +65.79% |
| Aug 2, 23 | -0.70 Decreased by -1.07 K% | -0.91 Increased by +23.08% |
| May 3, 23 | -1.10 Decreased by -13.40% | -0.89 Decreased by -23.60% |
| Feb 28, 23 | -0.78 Decreased by -212.00% | -0.84 Increased by +7.14% |
| Nov 2, 22 | -0.77 Decreased by -63.83% | -0.88 Increased by +12.50% |
| Aug 8, 22 | -0.06 Increased by +82.35% | -0.76 Increased by +92.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 61.49 M Increased by +66.15% | -6.91 M Increased by +63.29% | Decreased by -11.23% Increased by +77.91% |
| Jun 30, 23 | 50.14 M Increased by +43.92% | -18.78 M Decreased by -1.04 K% | Decreased by -37.45% Decreased by -691.69% |
| Mar 31, 23 | 42.04 M Increased by +56.55% | -29.20 M Decreased by -18.60% | Decreased by -69.47% Increased by +24.24% |
| Dec 31, 22 | 38.34 M Increased by +53.11% | -20.62 M Decreased by -220.65% | Decreased by -53.78% Decreased by -109.42% |
| Sep 30, 22 | 37.01 M Increased by +57.66% | -18.81 M Decreased by -59.54% | Decreased by -50.83% Decreased by -1.19% |
| Jun 30, 22 | 34.84 M Increased by +53.08% | -1.65 M Increased by +81.25% | Decreased by -4.73% Increased by +87.75% |
| Mar 31, 22 | 26.85 M Increased by +17.70% | -24.62 M Decreased by -475.30% | Decreased by -91.70% Decreased by -388.77% |
| Dec 31, 21 | 25.04 M Increased by +44.74% | -6.43 M Decreased by -31.52% | Decreased by -25.68% Increased by +9.14% |